357 related articles for article (PubMed ID: 30180878)
1. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
[TBL] [Abstract][Full Text] [Related]
2. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
4. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.
Sikora MJ; Cooper KL; Bahreini A; Luthra S; Wang G; Chandran UR; Davidson NE; Dabbs DJ; Welm AL; Oesterreich S
Cancer Res; 2014 Mar; 74(5):1463-74. PubMed ID: 24425047
[TBL] [Abstract][Full Text] [Related]
5. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
[TBL] [Abstract][Full Text] [Related]
6. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
Bacci M; Giannoni E; Fearns A; Ribas R; Gao Q; Taddei ML; Pintus G; Dowsett M; Isacke CM; Martin LA; Chiarugi P; Morandi A
Cancer Res; 2016 Mar; 76(6):1615-26. PubMed ID: 26795347
[TBL] [Abstract][Full Text] [Related]
7. Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.
Sreekumar S; Levine KM; Sikora MJ; Chen J; Tasdemir N; Carter D; Dabbs DJ; Meier C; Basudan A; Boone D; McAuliffe PF; Jankowitz RC; Lee AV; Atkinson JM; Oesterreich S
Endocrinology; 2020 Sep; 161(9):. PubMed ID: 32609836
[TBL] [Abstract][Full Text] [Related]
8. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.
Ribas R; Ghazoui Z; Gao Q; Pancholi S; Rani A; Dunbier A; Dowsett M; Martin LA
Breast Cancer Res; 2014 Oct; 16(5):447. PubMed ID: 25358600
[TBL] [Abstract][Full Text] [Related]
9. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast.
Sottnik JL; Bordeaux EK; Mehrotra S; Ferrara SE; Goodspeed AE; Costello JC; Sikora MJ
Mol Cancer Res; 2021 Aug; 19(8):1270-1282. PubMed ID: 33947745
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures.
Tasdemir N; Bossart EA; Li Z; Zhu L; Sikora MJ; Levine KM; Jacobsen BM; Tseng GC; Davidson NE; Oesterreich S
Cancer Res; 2018 Nov; 78(21):6209-6222. PubMed ID: 30228172
[TBL] [Abstract][Full Text] [Related]
11. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
13. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma.
Bossart EA; Tasdemir N; Sikora MJ; Bahreini A; Levine KM; Chen J; Basudan A; Jacobsen BM; Burns TF; Oesterreich S
Breast Cancer Res Treat; 2019 Jun; 175(2):327-337. PubMed ID: 30798422
[TBL] [Abstract][Full Text] [Related]
14. A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer.
Nayak SR; Harrington E; Boone D; Hartmaier R; Chen J; Pathiraja TN; Cooper KL; Fine JL; Sanfilippo J; Davidson NE; Lee AV; Dabbs D; Oesterreich S
Horm Cancer; 2015 Dec; 6(5-6):214-24. PubMed ID: 26113056
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Weigel MT; Ghazoui Z; Dunbier A; Pancholi S; Dowsett M; Martin LA
Breast Cancer Res; 2012 May; 14(3):R78. PubMed ID: 22608253
[TBL] [Abstract][Full Text] [Related]
16. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
17. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
18. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
19. Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.
Stires H; Heckler MM; Fu X; Li Z; Grasso CS; Quist MJ; Lewis JA; Klimach U; Zwart A; Mahajan A; Győrffy B; Cavalli LR; Riggins RB
Mol Cell Endocrinol; 2018 Aug; 471():105-117. PubMed ID: 28935545
[TBL] [Abstract][Full Text] [Related]
20. Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer.
Bahnassy S; Stires H; Jin L; Tam S; Mobin D; Balachandran M; Podar M; McCoy MD; Beckman RA; Riggins RB
Endocrinology; 2023 Nov; 164(12):. PubMed ID: 37897495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
